(12) Patent Application Publication (10) Pub. No.: US 2004/0180916A1 Levine (43) Pub

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2004/0180916A1 Levine (43) Pub US 20040180916A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0180916A1 Levine (43) Pub. Date: Sep. 16, 2004 (54) TREATMENT OF PAIN WITH Publication Classification COMBINATIONS OF NALBUPHINE AND OTHER KAPPA-OPOLD RECEPTOR (51) Int. Cl. ................................................ A61K 31/485 AGONSTS AND OPOLD RECEPTOR (52) U.S. Cl. .............................................................. 514/282 ANTAGONSTS (75) Inventor: Jon D. Levine, San Francisco, CA (US) (57) ABSTRACT Correspondence Address: TOWNSEND AND TOWNSEND AND CREW, LLP Methods and compositions for treating, managing or ame TWO EMBARCADERO CENTER liorating pain in a Subject (preferably, a mammal, and more EIGHTH FLOOR preferably, a human) comprising administration of a cen SAN FRANCISCO, CA 94111-3834 (US) trally acting (i.e., crosses the blood brain barrier) agonist of (73) Assignee: The Regents of the University of Cali a K-opioid receptor and a centrally acting opioid antagonist fornia, Oakland, CA Such that the analgesia achieved by this administration is greater than with administration of either the K-opioid (21) Appl. No.: 10/734,308 receptor agonist or the opioid antagonist alone. Preferably the K-opioid receptor is nalbuphine or a Salt or prodrug of (22) Filed: Dec. 12, 2003 nalbuphine and the opioid antagonist is naloxone or a Salt or Related U.S. Application Data prodrug of naloxone. Preferred methods of administration include mucosal (e.g. intranasal or pulmonary) and intrave (60) Provisional application No. 60/433,217, filed on Dec. nous. Other K-opioid receptors include pentazocine and 13, 2002. butorphanol. Patent Application Publication Sep. 16, 2004 Sheet 1 of 11 US 2004/0180916 A1 FIGURE 1. Males 1 Females Combined - a p a5 - Nalbuphine 2.5 mg Nalbuphine 5 mg Nalbuphine 10 mg -3 -3 -3 a -2 -2 -2 - -1 -1 -1 st(S 0 --- O O 1 d 2 2 2 3 3 3 3 4 4 4 -10 30 70 110 150 -10 30 70 110 150 -10 30 70 110 150 10 50 90 130 170 10 50 90 130 170 10 50 90 's 170 Time After Drug (min) PATIENTS RECEIVING 2.5MG 5 MG 10 MG -O-NALBUPHINE ALONE 31 33 30 -v- +NALOXONE 0.4 MG 30 30 26 -- NALOXONE 0.4 MGALONE 28 28 28 d valuupnine 4.0, 0, i u IIIy T valuMUI it V." Illy Males / Females Combined -N -4 E 9 -3 g -2 as -1 S -O-2.5MG (30 PATIENTS) 0 -v- 5MG (30 PATIENTS) 1 -- 10 MG (26 PATIENTS) 9, 2 3 C O 4 -10 1O 30 50 70 1000 to Time After Drug (min) Patent Application Publication Sep. 16, 2004 Sheet 2 of 11 US 2004/0180916A1 FIGURE 2 Males/femaleS COmbined a Nalbuphine 2.5 mg b Nalbuphine 5 mg C Nalbuphine 10 mg -4 -4 -4 5-3 -3 -3 5 -2 -2 -2 e 0 -1 -1 -1 0 O a O 1 1 1 5, 2 2 2 3 3 3 4. 4. 4. 288 R323 s 28, 2828 e 88s 828 &S Time after drug (min) 2.5 mg 5mg 10 mg -- naibuphine alone 26 33 30 -v- + naloxone 0.4 mg 27 30 25 -- naloxone 0.4 mg alone 28 28 28 d Nalbuphine 2.5, 5, 10 mg+naloxone 0.4 mg -4 O -O- 2.5 mg (27) -v- 5 mg (30) -- 10 mg (25) Patent Application Publication Sep. 16, 2004 Sheet 3 of 11 US 2004/018091.6 A1 FIGURE 3 NaIDupnine b mg t naIOXOne U.1, U.Z. & U.4 mg 3. Men b Women -o- 0.4 mg (14) -v- 0.2 mg (1) -o- 0.4 mg (n=16) -v- 0.2 mg (n=7) -- 0.1 mg (n=14) Cd Co o O C o O C C Co d d C. Cd d d Cd cd d d v vs N or v- N. w v- d to in o was N. y war ves vs was v. v. Time after drug (min) Patent Application Publication Sep. 16, 2004 Sheet 4 of 11 US 2004/0180916A1 FIGURE 4 Women b Men 2 -6 - nalbuphine (2.5 rpg). 3. -o- + naloxone (0.4rrig) Cd C C C Cd d to cd O Co v - co to N od v up a Time after drug (min) Patent Application Publication Sep. 16, 2004 Sheet 5 of 11 US 2004/0180916A1 FIGURES Nalbuphine 2.5 mg alone and + naloxone 0.2 mg (males co-varied for baseline pain) a Women b Men -O- alone (n=19) -o- alone (n=16) -v- 0.2 mg (n=15) -v- 0.2 mg (n=13) a da N CO & O. O. O. O. O. g g s s g g s Time after drug (min) Patent Application Publication Sep. 16, 2004 Sheet 6 of 11 US 2004/0180916A1 FIGURE 6 UU 90 80 Time of Drug Administration 70 (hrs in GCRC) E 9 60 -1- 1 9 -2- 2.5 9 50 -3- 5 5 -4- 7 C/D 40 -5- 11.5 CC -6- 14.5 D -7- 32 30 10 O Pain NauSea Pre- and 60 Minutes Post-drug Administration Patent Application Publication Sep. 16, 2004 Sheet 7 of 11 US 2004/018091.6 A1 FIGURE 7 Time of Drug Administration an (hrs in GCRC) 5 -1- 17.5 CD -2- 23.5 s -3- 33.5 O O?) 2 D Pain NauSea Pre- and 60 Minutes Post-drug Administration Patent Application Publication Sep. 16, 2004 Sheet 8 of 11 US 2004/0180916A1 FIGURE 8 100 90 Time of Drug Administration 80 (hrs in GCRC) 70 -1-2.5 E. -2- 3.5 9 60 -3- 4.5 9 -4- 16 SR 50 -5- 19 COO -6-21 -7 - 23.5 40 -8- 30 D -9- 32.5 30 -10-35 -11-38 20 -12- 41 10 4,9,10,11 O Pain NauSea Pre- and 60 Minutes Post-drug Administration Patent Application Publication Sep. 16, 2004 Sheet 9 of 11 US 2004/0180916A1 FIGURE 9 8.- : Q: --v-- Case 1: Male e --O-- Case 2: Female 5. 6- -O- Case 3: Female 9 O D O 2> . ? O 20 40 60 80 100 120 140 160 180 Post Injection (min) Patent Application Publication Sep. 16, 2004 Sheet 10 of 11 US 2004/0180916A1 FIGURE 10 Nerve injury Study (Nalbuphine 5 mg + Naloxone 04 mg) -10 10 30 50 70 90 110 130 150 170 Post Drug (min) Patent Application Publication Sep. 16, 2004 Sheet 11 of 11 US 2004/018091.6 A1 FIGURE 11 intra-nasal nalbuphine-naloxone combination -O- intra-nasal nalb 5 nbd0.4 (2) -v- i.v. nalb 5 nix 0.4 (14) -O- intra-nasal nalb 5 nix 0 (0) E 9. 9. C d is . S. 3. O)CC > . 3. -O- Intra-nasal nalb 5 nix 0.4 (2) -v- i.v. nalb 5 nix 0.4 (16) O -O- intra-nasal nalb 5 nib. O (1) O intra-nasal nalb 5 nib 0.4 (4) v. iv. naib 5 nix 0.4 (32) O Intra-nasal nalb 5 nib 0 (1) -10 10 30 50 7O 90 1 1 0 130 1501.70 US 2004/018091.6 A1 Sep. 16, 2004 TREATMENT OF PAIN WITH COMBINATIONS OF BRIEF SUMMARY OF INVENTION NALBUPHINE AND OTHER KAPPA-OPOD 0007. The present invention provides methods of treat RECEPTORAGONSTS AND OPOLD RECEPTOR ing, managing or ameliorating pain (including, e.g., inflam ANTAGONSTS matory pain, neuropathic pain, acute pain, chronic pain, CROSS-REFERENCES TO RELATED generalized pain Syndromes, post-operative and post-proce APPLICATIONS dural pain, etc.) in a Subject (preferably, a mammal, and more preferably, a human) comprising administration of a 0001. This application claims the benefit of the priority of centrally acting (i.e., crosses the blood brain barrier) agonist U.S. provisional application 60/433,217 filed Dec. 13, 2002, of a K-opioid receptor and a centrally acting opioid antago which is incorporated herein in its entirety. nist Such that the analgesia achieved by this administration is greater than with administration of either the K-opioid STATEMENT AS TO RIGHTS TO INVENTIONS receptor agonist or the opioid antagonist alone (in certain MADE UNDER FEDERALLY SPONSORED circumstances, analgesia is achieved by administration of RESEARCH OR DEVELOPMENT the combination whereas administration of the agonist or 0002 The invention was made with government support antagonist alone results in anti-analgesia or leSS analgesia under Grant Number NR 03923 of the National Institutes of than administration of the combination). Health. The government has certain rights in this invention. 0008. The invention further provides pharmaceutical compositions comprising combinations of a centrally acting FIELD OF INVENTION K-opioid agonist and an opioid antagonist that provide pain 0003. The present invention provides methods for treat relief greater than the pain relief achieved with either the ing, managing, and ameliorating pain, Such as pain, includ agonist or antagonist alone (and, preferably, greater than the ing inflammatory pain, neuropathic pain, acute and chronic additive analgesic effects of the agonist and antagonist on pain, and regional and generalized pain Syndromes while their own). The centrally acting K-opioid agonist may be a avoiding adverse side effects Such as abuse potential. In benzomorphan derivative, Such as, but not limited to, butor particular, the present invention provides methods of treat phanol, ketazocine, ethylketazocine, pentazocine, dezocine, ing, managing, and ameliorating pain by administration of a and bremazocine; a benzacetamide derivative, Such as, but generally low dose of a kappa opioid agonist with an opioid not limited to U50,488, U69,593, U62,066 (spiradoline), PD antagonist. The present invention also provides pharmaceu 117302, CI-977, DuP 747, ICI 197067, ICI 199441, BRL tical compositions, pharmaceutical kits, and combination 52537A, or BRL 52656A, a phenothiazine derivative, such therapies for treating, managing, and ameliorating pain.
Recommended publications
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Measures and CDS for Safer Opioid Prescribing: a Literature Review
    Measures and CDS for Safer Opioid Prescribing: A Literature Review Measures and CDS for Safer Opioid Prescribing: A Literature Review Executive Summary The U.S. opioid epidemic continues to pose significant challenges for patients, families, clinicians, and public health policy. Opioids are responsible for an estimated 315,000 deaths (from 1999 to 2016) and have caused 115 deaths per day.1 In 2017, the U.S. Department of Health and Human Services declared the opioid epidemic a public health crisis.2 The total economic burden of opioid abuse in the United States has been estimated to be $78.5 billion per year.3 Although providing care for chronic opioid users is important, equally vital are efforts to prevent so-called opioid-naïve patients (patients with no history of opioid use) from developing regular opioid use, misuse, or abuse. However, much remains unclear regarding what role clinician prescribing habits play and what duration or dose of opioids may safely be prescribed without promoting long-term use.4,5 In 2013, ECRI Institute convened the Partnership for Health IT Patient Safety, and its component, single-topic-focused workgroups followed. For this subject, the Electronic Health Record Association (EHRA): Measures and Clinical Decision Support (CDS) for Safer Opioid Prescribing workgroup included members from the Healthcare Information and Management Systems Society (HIMSS) EHRA and the Partnership team. The project was oriented towards exploring methods to enable a synergistic cycle of performance measurement and identifying electronic health record (EHR)/health information technology (IT)–enabled approaches to support healthcare organizations’ ability to assess and measure opioid prescribing.
    [Show full text]
  • Comparison Between Morphine and Morphine Plus Ketamine for Postoperative Pain Relief After Orthopaedic Surgery
    Ο University of Khartoum Faculty of Medicine Postgraduate Medical Studies Board Comparison between Morphine and Morphine plus Ketamine for postoperative pain relief after orthopaedic surgery By Dr. Sarah Mahmoud Nuri M.B.B.S, (University of Khartoum) A thesis submitted in partial fulfilment for the requirements of the degree of Clinical MD in anaesthesia & intensive care, May 2004 Supervisor Prof. Ali Ahmed Salama MBBS, DA, FFA Faculty of Medicine Neelain University To my mother ...... My grateful acknowledgement is made to Dr. Ali Ahmed Salama for his supervision, encouragement, and advice during the performance of this study. I'm also grateful to all orthopaedic registrars and house officers who helped me in collecting the data. I’m also grateful to Dr. Yassir Salih for his great help and support. I would like also to thank my family for their help and support. LIST OF ABBREVIATIONS CAMP Cyclic adenosine mono phosphate. PIP2 Phosphatidyl inositol di phosphate. IP3 Inositol tri phosphate. ADH Anti Diuretic Hormone. GF Glumerular Filtration. BP Blood Pressure. ECG Electro cadiogram. CBF Cerebral Blood Flow GI Gastro Intestinal CNS Central Nervous system ASA American Society of Anesthiologist VAS Visual analogue scale. NSAIDs Non steroidal anti infalammatory drugs. NMDA N-methyl- D- Aspartate GFR Glumerular filtration rate. EEG Electroencephalogram. ABSTRACT The aim of this study is detection of the efficacy of ketamine in low doses as a potent analgesic and it's ability to provide superior analgesia when added to morphine. It compared morphine with ketamine to morphine alone in Quasi experimental design of post surgical pain control . Also this study compared the incidence of morphine common side effects between the two groups.
    [Show full text]
  • Opioids Regulate Cgmp Formationin Cloned Neuroblastoma Cells
    Proc. NatL. Acad. Sci. USA Vol. 79, pp. 690-694, January 1982 Neurobiology Opioids regulate cGMP formation in cloned neuroblastoma cells (cyclic nucleotides/opiate receptor/desensitization) GERMAINE J. GWYNN AND ERMINIO COSTA* Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D.C. 20032 Communicated by Floyd E. Bloom, October 8, 1981 ABSTRACT Opioid agonists caused a rapid dose-related el- cumulation in rat striatal slices with characteristics that fulfill evation of the cGMP content of N4TG1 murine neuroblastoma the criteria for a specific narcotic action (6). In contrast, the cells. An excellent correlation was found between the rank order decrements in the cGMP content ofcerebellar tissue observed of potency of agonists in stimulating cGMP accumulation and in after morphine administration are probably indirect effects of displacing [3H]etorphine ([H]ETP) bound to intact cells. The nar- opioid receptor stimulation mediated by the modulation of y- cotic antagonists naloxone and diprenorphine failed to increase aminobutyric acid or acetylcholine collateral neuronal loops (7, cGMP content; moreover, in the presence of 5 ,IM naloxone, the 8). A functional role for cGMP in opioid action is further sug- EC50 of ETP increased from w9 nM to >1 ,uM. N4TG1 cells that had been incubated for 20 min with 0.32 ItM ETP and thoroughly gested by the pivotal role that calcium ions play both in regu- washed displayed a marked loss in sensitivity to subsequent ETP lating cGMP formation (for review, see refs. 9, 10) and in me- challenge. This desensitization was characterized by a 40-50% diating the acute and chronic effects ofopioids (for review, see decrease in maximal response and an increase in the apparent Ka refs.
    [Show full text]
  • '. Opiates Induce Long-Term Increases in Prodynorphin-Derived Peptide
    '. Nuunyn·Schm,cd(!bc'Q' G NauIIYII-Schrnicdcbcrg's Arch I'harlllacol (I<)X6) 33J :Jlil -3X6 Archives of Pharmacology Opiates induce long-term increases <!) Springcr-Vcrlag 1<)1(6 in prodynorphin-derived peptide levels in the guinea-pig myenteric plexus Riidi~cr Schull I , Katharina Mctlncr 1, Thomas Dandckar 1, and Christilln C,ramsch 1 I IIISlilul fiir Pharmakologie. Tllxikologie und Pharmazie. TieriirzllidlC Fakuiliil der Univcrsiliil Miinchcn. Ki.iniginslr. 16. D-liOOO Miinehcn 22. f-cderal Republic ofGcrmany 2 f)cparlrnenl of Ncurophamlacology. Max-l'lanck-lnslilul fUr Psychi'llric. Am Klopfcrspilz IXa. D-X033 Planegg-Marlinsried. Federal Republic of Germany Summary. The subcutaneous administration of a single dose during the state of morphine tolerance/dependence of an oriate agonist (levorphanol) or antagonist (naloxone) (Simantov and Snyder 1976). One investigation of the pe­ to guinea rigs results in an at least 3-fold elevation of ripheral nervous system revealed no changes in enkephalin dynorrhin and alpha-neoendorphin-immunoreactivity in concentrations in the myenteric plexus of the guinea-pig lhe longitudinal muscle myenteric rlexus preparation. The ileum upon chronic morphine exposure; however, eflccts arc time- and dose-dependent. significant elevations moderately increased levels of /I-cndorphin fragments were first' being observed 6 h after treatment and lasting for up observed (Opmeer et al. 19RO). to 24 h, Pretreatment levels of opioid pcptides were observed The data reported so far thus suggest that treatment of after 8 days, Combined injection of the narcotic agonist and animals with exogenous opioids may affect the concentra­ antagonist. at sufficiently high doses, resulted in an additive tions of some endogenous opioids but not of others.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 12/024482 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, ' February 2012 (09.02.2012) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 13/024,298 9 February 201 1 (09.02.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): QRX- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA LTD.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol
    Index AIDA, 495 Affinity labeling, analogs of (Cont.) cAMP, 409, 489 motphine,448 ATP, 409, 489 naltrexone, 449 [3H] ATP, 489 norlevotphanol,449 Absolute configuration normetazocine, 181 benzomotphans, 204 norpethidine, 232 levotphanol, 115 oripavine, 453 methadone and analogs, 316 oxymotphone, 449 motphine, 86 K-Agonists, 179,405,434 phenoperidine, 234 Aid in Interactive Drug Analysis, 495 piperazine derivatives, 399 [L-Ala2] dermotphin, 363 prodines and analogs, 272 [D-Ala, D-Leu] enkephalin (DADL), 68, 344 sinomenine, 28, 115 [D-Ala2 , Bugs] enkephalinamide, 347, 447 viminol, 400 [D-Ala2, Met'] enkephalinamide, 337, 346, Ac 61-91,360 371,489 Acetylcholine, 5, 407 [D-Ala2]leu-enkephalin, 344, 346, 348 Acetylcholine analogs, 186, 191 [D-Ala2] met-enkephalin, 348 l-Acetylcodeine, 32 [D-Ala2] enkephalins, 347 Acetylmethadols (a and (3) Alfentanil, 296 maintenance of addicts by a-isomer, 304, 309 (±)-I1(3-Alkylbenzomotphans, 167, 170 metabolism, 309 11(3-Alkylbenzomotphans, 204 N-allyl and N-CPM analogs, 310, 431 7-Alkylisomotphinans, 146 stereochemistry, 323 N-Alkylnorketobemidones, 431 synthesis, 309 N-Alkylnorpethidines, 233 X-ray crystallography, 327 N-Allylnormetazocine, 420 6-Acetylmotphine, receptor binding, 27 N-Allylnormotphine, 405 Acetylnormethadol, 323 N-Allylnorpethidine, 233 8(3-Acyldihydrocodeinones, 52 3-Allylprodines (a and (3), 256 14-Acyl-4,5-epoxymotphinans, 58 'H-NMR and stereochemistry, 256 7-Acylhydromotphones, 128 X-ray crystallography, 256 Addiction, 4 N-Allylnormetazocine, 420 Adenylate cyclase, 6, 409, 413, 424,
    [Show full text]
  • Symposium Iv. Discriminative Stimulus Effects
    Life Sciences, Vol. 28, pp. 1571-1584 Pergamon Press Printed in the U.S.A. MINI - SYMPOSIUM IV. DISCRIMINATIVE STIMULUS EFFECTS OF NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS Seymore Herling and James H. Woods Departments of Pharmacology and Psychology University of Michigan Ann Arbor, Michigan q8109 The different pharmacological syndromes produced by morphine and related drugs in the chronic spinal dog led Martin and his colleagues (1,2) to suggest that these drugs exert their agonist actions 0y interacting with three distinct receptors (~,K, and e). Morphine was hypothesized to be an agonist for the p receptor, ketazocine (ketocyclazocine) was an agonist for the K receptor, and SKF-10,0q7 was an agonist for the ~ receptor. The effects of these three drugs in the chronic spinal dog were reversed by the narcotic antagonist, naltrexone, indicating that the effects of these drugs are narcotic agonist effects (I). In additlon to the different effects of these narcotics in the non- dependent chronic spinal dog, the effects of morphine, ketazocine, and SKF-IO,047 in several other behavioral and physiological preparations are consistent with the concept of multiple receptors. For example, while ketazocine and ethylketazocine, like morphine, produce analgesia, these compounds, unlike morphine, do not suppress signs of narcotic abstinence in the morphine-dependent rhesus monkey or morphine-dependent chronic spinal dog (1-5). Further, the characteristics of ketazocine withdrawal and antagonist- precipitated abstinence syndromes, although similar to those of cyclazocine, are quailtativeiy different from those of morphine (1,2). In rhesus monkeys, ketazocine, ethylketazocine, and SKF-10,047 maintain lever pressing at rates comparable to or below those maintained by saline, and well below response rates maintained by codeine or morphine (5,6), suggesting that the former set of drugs have limited reinforcing effect.
    [Show full text]
  • Psychoactive Natural Products: Overview of Recent Developments
    12 Ann Ist Super Sanità 2014 | Vol. 50, No. 1: 12-27 DOI: 10.4415/ANN_14_01_04 Psychoactive natural products: overview of recent developments István Ujváry REVIEWS iKem BT, Budapest, Hungary AND Abstract Natural psychoactive substances have fascinated the curious mind of shamans, artists, Key words ARTICLES scholars and laymen since antiquity. During the twentieth century, the chemical com- • ethnopharmacology position of the most important psychoactive drugs, that is opium, cannabis, coca and • mode of action “magic mushrooms”, has been fully elucidated. The mode of action of the principal in- • natural products gredients has also been deciphered at the molecular level. In the past two decades, the • psychopharmacology RIGINAL use of herbal drugs, such as kava, kratom and Salvia divinorum, began to spread beyond • toxicology O their traditional geographical and cultural boundaries. The aim of the present paper is to briefly summarize recent findings on the psychopharmacology of the most prominent psychoactive natural products. Current knowledge on a few lesser-known drugs, includ- ing bufotenine, glaucine, kava, betel, pituri, lettuce opium and kanna is also reviewed. In addition, selected cases of alleged natural (or semi-natural) products are also mentioned. O, mickle is the powerful grace that lies In herbs, plants, stones, and their true qualities William Shakespeare (Romeo and Juliet) INTRODUCTION Historical background of psychoactive natural During the past 200 years, there has been major pro- products research gress in our understanding of the composition and ef- The biochemical machinery of an organism generates fects of many psychoactive natural products, particular- many structurally related chemicals (Nature’s “combinato- ly those that have therapeutic uses.
    [Show full text]